Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, cancer and Type 1 diabetes. The IPSC news feed on Stock Titan aggregates company announcements, press releases and regulatory updates so readers can follow how Century Therapeutics communicates progress on its pipeline and corporate strategy.
According to the company’s public disclosures, key news themes include updates on clinical and preclinical programs such as CNTY-101 for B-cell-mediated autoimmune diseases, CNTY-308 as a CD19-targeted CAR-iT therapy, and CNTY-813, an iPSC-derived beta islet program for Type 1 diabetes. News items also cover scientific presentations at conferences, where Century Therapeutics shares data on Allo-Evasion™ 5.0, CAR-NK and CAR-T platforms, and iPSC-derived non-immune cell programs.
Investors and followers of IPSC can also find coverage of quarterly financial results, cash runway commentary, and organizational changes such as workforce adjustments, board appointments and executive role updates. Capital markets events, including private placement financings and participation in healthcare investment conferences, are typically disclosed through press releases and associated Form 8-K filings.
By reviewing the IPSC news stream, readers can see how Century Therapeutics describes the evolution of its iPSC cell foundry, its focus on B-cell-mediated diseases and oncology, and its efforts to advance off-the-shelf cell therapies. Bookmark this page to access a consolidated view of Century Therapeutics’ latest public communications as they are released.
Century Therapeutics (NASDAQ: IPSC) has announced a strategic portfolio prioritization aimed at extending its cash runway into 2026. The company will focus on CNTY-101 for relapsed/refractory B-cell lymphoma and CNTY-107 for Nectin-4+ tumors, while de-prioritizing CNTY-103 for glioblastoma. A workforce reduction of approximately 25% has been implemented to support this strategy. The Phase 1 study of CNTY-101 remains on track, with no impact on the partnered programs with Bristol Myers Squibb. CEO Lalo Flores emphasizes the importance of these changes for achieving key development milestones.
Century Therapeutics (NASDAQ: IPSC) will have its CEO, Lalo Flores, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 AM PT. As a biotechnology company specializing in iPSC-derived cell therapies for cancer treatment, Century aims to address the limitations of traditional therapies. A live webcast of the presentation will be available on their website, with a replay accessible for a limited time. For more company insights, visit Century Therapeutics.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 2:00 PM ET. A live webcast of the event will be accessible on the company's website, with an archived replay available for a limited time. The company focuses on developing iPSC-derived cell therapies to address cancer, leveraging advanced cellular reprogramming and genetic engineering. Their goal is to create off-the-shelf cell therapies that enhance patient access and improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) announced significant preclinical advancements in its iPSC-derived cell therapy platform, showcased at the SITC 37th Annual Meeting. Key highlights include effective anti-tumor activity of iPSC-derived CAR gamma delta T cells and the nomination of CNTY-107, targeting Nectin-4 for solid tumors, with an IND filing expected in 2025. The company is enhancing its iNK cell platform, focusing on genetic modifications for improved efficacy and safety. Century is set to provide further insights during a virtual R&D Day on November 11, 2022.
Century Therapeutics (NASDAQ: IPSC) reported its third-quarter 2022 results, revealing a cash position of $395.3 million and a net loss of $30.7 million. The company expects to initiate the Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies soon. R&D expenses increased to $25.9 million, primarily due to higher personnel costs. Century has reduced its GAAP operating expenses guidance for 2022 to $140 million to $145 million, and forecasts a cash runway into 2025.
Century Therapeutics (NASDAQ: IPSC) will host a virtual Research and Development Day on November 11, 2022, from 8:00 AM to 9:30 AM ET. This event will feature presentations from the management team and Dr. Jonathan Rosenberg from Memorial Sloan Kettering Cancer Center, focused on the company's solid tumor strategy and gamma delta iT cell platform. Preclinical data will also be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting. More details can be found on the company's website under Events & Presentations.
Century Therapeutics (NASDAQ: IPSC) announced that it will present preclinical data from its iPSC-based cell therapy platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting, scheduled for November 8-12, 2022, in Boston. The company will showcase two poster presentations: one focusing on enhancing iNK cell therapies for better anti-tumor efficacy on November 10, and the other on targeting solid tumors with iPSC-derived CAR T cells on November 11. These advancements underline the company's commitment to innovative cancer therapies.
Century Therapeutics (NASDAQ: IPSC) appointed Daphne Quimi and Timothy Walbert to its Board of Directors as part of a strategic move to enhance its leadership. Quimi, currently CFO of Amicus Therapeutics, brings extensive experience in finance and accounting, while Walbert, CEO of Horizon Therapeutics, adds expertise in product commercialization. The announcement also disclosed the resignation of Eli Casdin from the Board, effective October 1, 2022. These changes aim to accelerate the company's development of innovative cell therapies for cancer treatment.
Century Therapeutics (NASDAQ: IPSC) announced CEO Lalo Flores will join the panel discussion on “Next Generation Gene Editing” at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 10:30 AM ET. This participation highlights the company's focus on developing iPSC-derived cell therapies for cancer treatment. A live webcast of the event will be available on their website, with a replay archived for a limited time.
Century Therapeutics (NASDAQ: IPSC) announced that Chief Operations Officer Adrienne Farid, Ph.D., will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 9:00 AM ET. The event will be available via live webcast on the company's website, with an archive for later viewing. Century is focused on developing cell therapies for cancer using induced pluripotent stem cells, aiming to improve patient access to innovative treatments. The company emphasizes its expertise in genetic engineering and cellular reprogramming to overcome challenges in the current cell therapy landscape.